Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Purchased by Jennison Associates LLC

Jennison Associates LLC boosted its stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA) by 14.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 1,626,628 shares of the company’s stock after acquiring an additional 204,261 shares during the period. Jennison Associates LLC’s holdings in Cabaletta Bio were worth $36,924,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in shares of Cabaletta Bio by 14.3% during the third quarter. Vanguard Group Inc. now owns 1,968,108 shares of the company’s stock worth $29,955,000 after buying an additional 246,596 shares in the last quarter. Swiss National Bank acquired a new position in Cabaletta Bio during the 3rd quarter worth approximately $930,000. Citigroup Inc. increased its position in shares of Cabaletta Bio by 552.4% in the 3rd quarter. Citigroup Inc. now owns 49,695 shares of the company’s stock valued at $756,000 after purchasing an additional 42,078 shares during the last quarter. Wellington Management Group LLP purchased a new stake in shares of Cabaletta Bio in the 3rd quarter valued at approximately $3,753,000. Finally, Rafferty Asset Management LLC acquired a new stake in shares of Cabaletta Bio in the 3rd quarter valued at $1,798,000.

Cabaletta Bio Stock Down 2.7 %

CABA opened at $12.96 on Thursday. Cabaletta Bio, Inc. has a 52 week low of $7.69 and a 52 week high of $26.35. The business’s 50 day moving average is $18.96 and its two-hundred day moving average is $18.92.

Cabaletta Bio (NASDAQ:CABA) last announced its earnings results on Thursday, March 21st. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.07). Sell-side analysts forecast that Cabaletta Bio, Inc. will post -1.82 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on CABA shares. Jefferies Financial Group initiated coverage on Cabaletta Bio in a report on Monday, February 5th. They issued a “buy” rating and a $36.00 target price on the stock. Wells Fargo & Company increased their price objective on Cabaletta Bio from $34.00 to $35.00 and gave the company an “overweight” rating in a report on Friday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and set a $50.00 target price on shares of Cabaletta Bio in a research report on Friday, April 5th. HC Wainwright upped their price target on Cabaletta Bio from $25.00 to $30.00 and gave the company a “buy” rating in a report on Friday, March 22nd. Finally, Citigroup raised their price objective on shares of Cabaletta Bio from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, April 4th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $34.33.

Cabaletta Bio Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.